FierceBiotechOriginal article
{"a":[{"_":"Agenus scraps phase 3 colorectal study after 3 months to narrow focus to colon cancer","$":{"href":"/biotech/agenus-scraps-phase-3-colorectal-study-after-3-months-narrow-focus-colon-cancer","hreflang":"en"}}]}
Phase 3negativeNegative
AI Analysis
Summary
Agenus discontinued its Phase 3 combination therapy study in colorectal cancer after three months to refocus efforts on colon cancer. The early termination indicates a strategic pivot and potential setback in the broader colorectal cancer program.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Phase 3 study scrapped after 3 months; company narrowing focus to colon cancer
Importance:6/10
Sentiment:
-0.80
Phase 3 terminationcolorectal cancercolon cancerstudy discontinuationdevelopment strategy shift
Related Companies
Read the original article
Published by FierceBiotech on July 13, 2026 7:59 AM